Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Some Free DD for the Stockhouse crowd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Comment by Arbourmarkon Jul 22, 2020 8:05am
145 Views
Post# 31300570

RE:RE:RE:RE:Some Free DD for the Stockhouse crowd

RE:RE:RE:RE:Some Free DD for the Stockhouse crowdAlgernon,

You make some valid points and are a valuable contributor here but I would like at the failure of the South Korean trial was due to a lack of patients and in my opinion the extraordinary measures take by the South Korean government to test and contain the virus. Yes it made sense to do the study where the drug was already approved but honestly I feel using words to suggest the company dropped the ball is not accurate and only suggests that management was responsible for this.

I am confident that with announcement that they are working with a Miami institution the new epicenter for Covid-19 they will have no problem enrolling patients. I suspect we should have multiple news releases in the coming weeks.

Respectfully

Mark
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities